Team2 Solutions, LLC — Medford, Oregon

Team2 Solutions, LLC is a clinical research site located in Medford, Oregon, United States 97504.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Team2 Solutions, LLC has participated in 1 clinical trials.

Therapeutic areas: Vertebra; Degeneration, Spinal Trauma, Spinal Deformity.

Sponsors: NuVasive.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Medford

Browse all research sites in Oregon · View every site in Medford

• GSK Investigational Site
• Research Site
• Velocity Clinical Research Medford
• Asante Rogue Regional Medical Center
• Novartis Investigative Site
• Clinical Research Institute of Southern Oregon PC
• Providence Medford Medical Center
• Sunstone Medical Research
• Pfizer Investigational Site
• Rogue Valley Medical Center
• Velocity Clinical Research
• Duramed Investigational Site

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Team2 Solutions, LLC?

Team2 Solutions, LLC has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Team2 Solutions, LLC conducted?

Team2 Solutions, LLC has 1 clinical trials on record. Their work covers Vertebra; Degeneration, Spinal Trauma, Spinal Deformity.

Is Team2 Solutions, LLC accredited by Crixeo Clinical Trials?

Team2 Solutions, LLC has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Team2 Solutions, LLC?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.